Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Terminated Phase 2 Interventional Results available

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

NCT00490776
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 31, 2026, 8:51 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Dimensional Changes: Randomized Clinical Trial

NCT05684068
View directory record Official record
Conditions
Gingival Recession
Interventions
Gum Graft Placed on Denuded Bone, Gum Graft Placed on Split Thickness Periosteal Bed Preparation
Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity

NCT03238352
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Potassium oxalate, Sodium fluoride, Placebo
Device · Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

NCT03022617
View directory record Official record
Conditions
Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 31, 2026, 8:51 AM EDT
Withdrawn Not applicable Interventional

Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis

NCT00275379
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
13
States / cities
Glendora, California • Redding, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

NCT04178577
View directory record Official record
Conditions
Renal Impairment
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

NCT01600859
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
E2609, Placebo for E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 31, 2026, 8:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

NCT06714253
View directory record Official record
Conditions
Radiation-Induced Xerostomia and Hyposalivation
Interventions
RXRG001, Placebo
Biological
Lead sponsor
RiboX Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 8:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors

NCT01272570
View directory record Official record
Conditions
Breast Cancer, Xerostomia
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 31, 2026, 8:51 AM EDT
Terminated No phase listed Observational

Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors

NCT01137162
View directory record Official record
Conditions
Anal, Colon, and Rectal Cancers, Head and Neck Cancer, Lung Cancer, Colon Cancer, Colonic Neoplasms, Colorectal Neoplasms, Colon/Rectal Cancer, Colon/Rectal Cancer Colon Cancer, Colon/Rectal Cancer Rectal Cancer, Colon/Rectal Cancer Anal Cancer, Head and Neck Cancers, Head and Neck Cancers Lip, Head and Neck Cancers Oral Cavity, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oropharynx, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Trachea, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC)
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

NCT00503451
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Neoplasms
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 31, 2026, 8:51 AM EDT
Recruiting Phase 3 Interventional

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Escondido, California • Huntington Park, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

NCT02877641
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Weakness
Interventions
Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin, Placebo, Questionnaire Administration
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Results available

Boiled Peanut Oral Immunotherapy

NCT04090203
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Boiled Peanut Powder
Drug
Lead sponsor
Alton Melton
Other
Eligibility
1 Year to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 8:51 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903
View directory record Official record
Conditions
Obesity, Overweight, Overweight or Obesity
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
43
States / cities
Chandler, Arizona • Sun City West, Arizona • Concord, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment

NCT04931095
View directory record Official record
Conditions
Cannabis Intoxication, Alcohol Intoxication
Interventions
Cannabis, Alcohol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting

NCT02174198
View directory record Official record
Conditions
Tooth Loss
Interventions
BioOss Collagen at the time of implant placement
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

NCT06182267
View directory record Official record
Conditions
Caries,Dental
Interventions
L Arginine, Sodium Fluoride
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial

NCT03241511
View directory record Official record
Conditions
Chronic Periodontitis, End Stage Renal Disease
Interventions
Test
Other
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00323934
View directory record Official record
Conditions
Tumors, Non Hodgkin's Lymphoma
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 31, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance

NCT02405000
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Intraoperative CT imaging
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 31, 2026, 8:51 AM EDT